{"ticker": {"uuid": "932d750f-7374-4126-b519-14313f9c835e", "symbol": "PFE", "name": "Pfizer Inc", "exchange": "NYSE", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - General"}, "articles": [{"title": "Is Earlier\u2011Stage PADCEV\u2011Keytruda Approval Reshaping The Investment Case For Pfizer (PFE)?", "summary": "Pfizer and Astellas recently secured FDA approval for PADCEV plus Keytruda for earlier-stage muscle-invasive bladder cancer, which broadens PADCEV\u2019s application and reinforces Pfizer's oncology focus. While this strengthens Pfizer\u2019s near-term cancer pipeline, the article notes th", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-pfe/pfizer/news/is-earlierstage-padcevkeytruda-approval-reshaping-the-invest", "source_name": "Simply Wall Street", "published_at": "2026-07-16T00:41:07", "published_display": "16 Jul 2026 00:41", "sentiment": "positive", "sentiment_pct": 62, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pfizer (NYSE:PFE) Faces New Patent Claim After $96 Billion in COVID Vaccine Revenue", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNWHpvSjBpa0ZYSi0tcWNuYWF1b2YxdVJNUzI2dmxKMUJxbTI2T2NCUHlIbHg3Q0doZ1VwTVZVa2hyUktfY1E2aE5IaC1NTlBrNjNCc3NwUHktdEVTekxkbHZGVTEyNHF1NzVURzJsT1A0b3V0QWxLQ1VpVnkwcHBoUTVwVXB5dlV5VjhnMGFGSmNkYTYtX0lIUkJBY2l2NTJnOEE?oc=5", "source_name": "TechStock\u00b2", "published_at": "2026-07-15T21:47:41+00:00", "published_display": "15 Jul 2026 21:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pfizer Inc. stock outperforms competitors on strong trading day", "summary": "Pfizer Inc. (PFE) saw its stock rise by 2.35% to $24.82 on Wednesday, outperforming the broader market as both the S&P 500 and Dow Jones Industrial Average also posted gains. The company's stock closed 13.65% below its 52-week high of $28.75, which was set on April 2nd. This perf", "url": "https://www.marketwatch.com/data-news/pfizer-inc-stock-outperforms-competitors-on-strong-trading-day-b26b3cad-228b8da1cb3c?mod=mw_quote_news", "source_name": "MarketWatch", "published_at": "2026-07-15T16:36:00", "published_display": "15 Jul 2026 16:36", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sanofi sues Pfizer, Moderna over COVID shot technology", "summary": "Sanofi has filed lawsuits against Pfizer and Moderna, alleging that their COVID-19 vaccines infringe on multiple patents held by the French pharmaceutical company. The lawsuits claim that the mRNA innovations used in Pfizer and Moderna's blockbuster vaccines violate Sanofi's pate", "url": "https://www.reuters.com/legal/litigation/sanofi-sues-pfizer-moderna-over-covid-shot-technology-2026-07-15/", "source_name": "Reuters", "published_at": "2026-07-15T16:04:03", "published_display": "15 Jul 2026 16:04", "sentiment": "negative", "sentiment_pct": 33, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sanofi Sues Moderna, Pfizer for Vaccine-Tech Patent Royalties", "summary": "Sanofi has filed federal lawsuits against Moderna and Pfizer, seeking patent royalties for their COVID-19 and RSV vaccines. Sanofi alleges that Moderna's Spikevax, mNexspike, and mResvia vaccines, and Pfizer's Comirnaty vaccine, infringe upon as many as 10 mRNA delivery patents h", "url": "https://news.bloomberglaw.com/ip-law/sanofi-sues-moderna-pfizer-for-vaccine-tech-patent-royalties", "source_name": "Bloomberg Law News", "published_at": "2026-07-15T14:59:10", "published_display": "15 Jul 2026 14:59", "sentiment": "negative", "sentiment_pct": 40, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pfizer (PFE) Announces FDA Approval of PADCEV plus Keytruda in MIBC", "summary": "Pfizer and Astellas Pharma announced FDA approval of PADCEV plus Keytruda as a neoadjuvant and adjuvant treatment for adult patients with muscle-invasive bladder cancer (MIBC), marking the first platinum-free regimen approved for MIBC regardless of cisplatin eligibility. This app", "url": "https://finance.yahoo.com/healthcare/articles/pfizer-pfe-announces-fda-approval-142445150.html", "source_name": "Market source", "published_at": "2026-07-15T14:24:46", "published_display": "15 Jul 2026 14:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is the Bearishness Around Pfizer and Gilead Sciences a Contrarian Opportunity?", "summary": "Pfizer and Gilead Sciences are presenting a contrarian investment opportunity as both stocks have experienced \"death crosses\" but trade below Wall Street consensus targets. Pfizer appears to be the more compelling contrarian setup due to its attractive 8x forward P/E and 7% divid", "url": "https://247wallst.com/investing/2026/07/15/is-the-bearishness-around-pfizer-and-gilead-sciences-a-contrarian-opportunity/", "source_name": "24/7 Wall St.", "published_at": "2026-07-15T13:10:37", "published_display": "15 Jul 2026 13:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celcuity gains FDA approval for closely-watched breast cancer drug", "summary": "Celcuity received FDA approval for its breast cancer drug Revtorpyk, to be used in combination with hormone therapy and Pfizer\u2019s Ibrance for certain advanced ER-positive, HER2-negative patients. Despite this regulatory win, Celcuity's shares fell due to unexpected launch timing a", "url": "https://finance.yahoo.com/healthcare/articles/celcuity-gains-fda-approval-closely-121800691.html", "source_name": "Market source", "published_at": "2026-07-15T07:18:00", "published_display": "15 Jul 2026 07:18", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pfizer (PFE) Wins FDA Approval For First Platinum Free Bladder Cancer Regimen", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/pfizer-pfe-wins-fda-approval-221544395.html", "source_name": "Simply Wall St.", "published_at": "2026-07-14T22:15:44+00:00", "published_display": "14 Jul 2026 22:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Structural Failure at Pfizer Conversion Project Triggers Citywide Construction Review", "summary": "A structural failure at the former Pfizer headquarters conversion project into 1,600 apartments in New York City has led to a citywide safety inspection of construction sites. Two steel columns buckled, causing floors to sag and prompting evacuations, raising concerns among inves", "url": "https://propmodo.com/structural-failure-at-pfizer-conversion-project-triggers-citywide-construction-review/", "source_name": "Propmodo", "published_at": "2026-07-14T22:09:05", "published_display": "14 Jul 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CELC Stock Clocks Best Day In About 2 Months On First FDA Approval For Cancer Drug", "summary": "Celcuity Inc. (CELC) shares surged 7% after the FDA approved its cancer drug, gedatolisib, in combination with fulvestrant, with or without Pfizer's palbociclib, for advanced hormone receptor-positive, HER2-negative breast cancer. This marks Celcuity's first marketed product, tra", "url": "https://finance.yahoo.com/healthcare/articles/celc-stock-clocks-best-day-212445145.html", "source_name": "Market source", "published_at": "2026-07-14T21:24:00", "published_display": "14 Jul 2026 21:24", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pfizer (PFE) Stock Looks Fully Priced After Its 21% Slump", "summary": "Pfizer (PFE) shares have declined by 21% over the past five years, placing its current valuation in a neutral position\u2014neither clearly cheap nor expensive. The stock trades at a P/E ratio of 18.7x, close to Simply Wall St's fair P/E of 19.6x, suggesting it is fairly valued within", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-pfe/pfizer/news/pfizer-pfe-stock-looks-fully-priced-after-its-21-slump", "source_name": "Simply Wall Street", "published_at": "2026-07-14T17:40:45", "published_display": "14 Jul 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pfizer Vs. Amgen: Bet That Pfizer's Seagen Integration Leads to Long-Term Oncology Alpha Over Amgen", "summary": "This article contrasts Pfizer and Amgen, arguing that Pfizer offers a better investment in oncology due to its successful integration of Seagen and existing revenue streams. Pfizer trades at a lower forward P/E of 8x with a substantial 7% dividend yield, while Amgen faces signifi", "url": "https://247wallst.com/investing/2026/07/14/pfizer-vs-amgen-bet-that-pfizers-seagen-integration-leads-to-long-term-oncology-alpha-over-amgen/", "source_name": "24/7 Wall St.", "published_at": "2026-07-14T15:51:00", "published_display": "14 Jul 2026 15:51", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pfizer Has the Highest-Yielding Dividend in the S&P 500. Should Investors Be Worried?", "summary": "Pfizer currently boasts the highest dividend yield in the S&P 500 at 7.1%, which is significantly above the average, leading some investors to worry about the safety of its dividend. While the high yield is partly due to a volatile share price, the company's recent earnings show ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/PFE/pressreleases/3276380/pfizer-has-the-highest-yielding-dividend-in-the-sp-500-should-investors-be-worried/", "source_name": "The Globe and Mail", "published_at": "2026-07-14T15:04:22", "published_display": "14 Jul 2026 15:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's What to Expect From Pfizer's Next Earnings Report", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNWXhwWVBRSW1NU094SEpZRU91S2RlTGVONmd2TUlCNVc2SUM5R1Q0am96ZFBmcDhPb0dXcE5fbExULTJNeFo4WHdQc0xEVGluNlVsN3dyaC1jM0ZaY1A3X3hfbEN5TTNuR2txWFdFNkpnUmlEdW1ER1JLOW13b09yUTVFUWtLOUJPcWhWS2Q0T3dDWXQ5dzRpdlljQm1uSGJP?oc=5", "source_name": "Market source", "published_at": "2026-07-14T14:02:32+00:00", "published_display": "14 Jul 2026 14:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's How Pfizer's Oncology Growth Story Looks Ahead of Q2 Results", "summary": "Pfizer is a leading oncology drugmaker, with oncology sales comprising about 27% of its total revenues. The company will announce its Q2 2026 results on August 4, with expectations of growth driven by drugs like Padcev, Lorbrena, and the Braftovi-Mektovi combination, alongside co", "url": "https://www.tradingview.com/news/zacks:349f5d7d4094b:0-here-s-how-pfizer-s-oncology-growth-story-looks-ahead-of-q2-results/", "source_name": "TradingView", "published_at": "2026-07-14T14:08:41", "published_display": "14 Jul 2026 14:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PFE stock holds steady as Pfizer focuses on core pharma portfolio", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxOWGJZXzNlNG9OSm1DaERNLXlCaDlJQXB4OTd0WkU2TGdFQy13a3c5UlZadWw1eVFqWEJFNVIwSlA4amJJUHdoZms5ZFVKbVBjTUlwZ3ZqdmJ5QU40RzJHMkdhV1RZdnVaTm95SmpOQ24tODN6ZHNSdjN6TFZTU1A5UE9NMzk2ZTJ2ajFZeU50ekRBVGNFYlBRWGJLcXFLVTYzYVRmdS15QUhFckFkSGdYT2pRamFFX1NQaE1qVUlkLU5iUQ?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-07-11T19:44:50+00:00", "published_display": "11 Jul 2026 19:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pfizer Stock Leads 3 AI Healthcare Picks Worth A Closer Look", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNNzlOaTl1Y1BydzVlbTk1eTR1S3J2RzltMXZ2dG9LcTlhTTY4LUJyMFJuOWFXOVpEZGVjTkRfYVRZY2k3RkR2eXFKTFFrc00tNE4taC1uSFRHM2NIajBaNTdJa2lEcVdwXzVSblF6d21kM1pmd3Izb3dtcGxEUDkyR204RXRZNl9HM1NfeWF1Y1BzT012YjhRRzBURE9qd1d4aXlyNHFHOXRKX1dueXQ5R0ZR?oc=5", "source_name": "Sahm", "published_at": "2026-07-10T07:00:00+00:00", "published_display": "10 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pfizer (PFE) Stock Sinks As Market Gains: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxNd1Q0MzYyc0JtUmFoanl5dGpTem9jcEdKX3lNLVRyb2x2Zk9nYW1BeW9RLWRJMGYzSmQ1Rm9QZHZ1MWZ1UkpwSXdCSk52dms0UF9SV2UxeC1VelVUaFdockhrWjhQejFHQzBxdWlBanp0UkFIeXBrczZGMVNHNkhsdHIzNHp3RkVJelI4VG5LWTNnUml6SEMwUy1n?oc=5", "source_name": "Market source", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pfizer Stock And 2 AI Healthcare Picks Investors May Want To Watch", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPczZzYmZKVXJQVjRibkVSQTVNVm4wWWZVVkxTdWhWdHpGQjlHdnhiZFNFeVo1clVGX3dGZDROaHdpQVVhMzd4X004MFFLRjJqcHVSYi0zUmlOYnI1bnppVWZocjNQUzQtcm1YVWpqSVVObXNXQjlaaGp1UFNYQm1MUUlFNDlPNGtweFVOcWE0WlBnSUg2bVhzY3UxNUhPT3BSeTE4MjdwN25xcHhSd0dyYnY1Y1Y0UlZmYkE?oc=5", "source_name": "Sahm", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pfizer (PFE) Stock May Be Fairly Priced On Its 22% Slide", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pfizer's CEO Says His Company Has a \"Very Big Balance Sheet\" to Do Deals. Here's the Perfect Next Acquisition Target for the Pharma Giant.", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxQQmFsaDgzZFl6bE5kNGVCcXo3aHQ2NWg3RUg2RnBCY1lqRWlvZFRCRDZsQUNxUURzdGtHNHBXUXgwaXN1VjhsMkVUNjdFbllTT2hMUDBlZXBsek1ieTJUTVJ5TUJtUW15Z2djV2dLYjhueHp6WGlCZHZFaXlsWURCSDdBZVdiT2hkQW5TdTZwMURrZDBY?oc=5", "source_name": "Market source", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pfizer vs Verizon Communications: Which High-Yielding Dividend Stock Is the Better Buy?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZVN0Mm1MbVVHeWxmOTJVUmtjQXVSd1JBNDlFdXdvaF9naDZ3SUFlelprRkxOTFdWYlc4R01maGh5Mzg3RVludGhGWEJCbXQwTldPSWpVeGZ6blV0NmVvUHIzNkx0S0p2ak11Z0JrYlpoaVpTb19aazdXQ19UNzVSV3dDbFZVU0pjWEUzRmhET2Z5YjRPM0FoZ3VmMXkzbEtJWDRFYQ?oc=5", "source_name": "Market source", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Pfizer (PFE) Stock Undervalued Despite Mixed Oncology Progress?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPRkFfTW1SRnRIbGhvUnVtZXZEYnBfVkYyNUljN053RUFOdHRFeXFZTmtwT0k3NlZLYkFyRXZ3MUVHaHJHSlJ0eWN5V3ZsOXlUS0xPamFHd2ZSZmZ4TDl1d1Y2M0RadFJtZ09iU01WdzU3bnZNV2J5WllmRFhMYnZWa245dW5VX3pqdW8yemJMMFlpa2JWZkpJOVpxUFZoeXFwUm93?oc=5", "source_name": "Market source", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pfizer (PFE) Stock Declines While Market Improves: Some Information for Investors", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNY0tRMEFHVTZfMl9weDBXMGdVSEFuVWRrN3ZtTk1kV1ZvczlnQ0hwMk5tX19NU0pBS0VfZWhERlNJelJzWGNLQWdHR2xPVGh5OXJVVGdBa3AtSnZMQlIwQTM1QUV5OEY1cFU2RUxhLVJ0Y1VWbG1PcmFUZm1HS05MamszX1k0QjJFRU5nWG9VN2ZKb2dDXzBZSmJTeEs?oc=5", "source_name": "Market source", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Pfizer Inc. (PFE) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOMk1TZ0EySmVsUmY0WXREekdZS2VQd1Q2dmpIRl8yX1dkdW8wMUIxTTFzN1FuTU9HUFZBQWJHOEd6ekU4QnNaZDZGVC1rRDVsaFdTUTVRZXBrLWxKSUM3Qi1xUXlwMGl0OWJ5NG01NWw3TkdraF80bVJuck1FTmNTbUxIWE84MWRVTkVieDBkbzlndEto?oc=5", "source_name": "Market source", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Opinion: Pfizer Is a Fantastic Dividend Stock for Income Investors to Buy Right Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOUkJhdGdKXzNZRVFXRWVHUTU1MHdzbW1GWno4dEV1VjdUQ3lJZFFQN2RoVXNGcUtadkZmUFNMcHFUQ0d0cUZDNVFFS04zbGNMUzB6SmpzV281ME93UjJNNURUSnJPR1lZaThDMGZZT3ZQeGRsQ2pZRDlRN094Y2drcjdQUFdIN1B1cVJrbGl2WExWRHJpRURWcVZoMTBHS2J1Y2c?oc=5", "source_name": "Market source", "published_at": "2026-06-27T07:00:00+00:00", "published_display": "27 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pfizer Declares Third-Quarter 2026 Dividend", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNRHNqVjBjcGJQd0g0SGhFNkdlVll5dmVqc1JVdjFTajJrX0lDWVVoNXprbWZtR09mdDItUDduRHNXVjd4TnhIRDJ4bGlmczdxdkFtd1JYT08yVy1wY2JqeEVhQ3JpTjBOR0YtSFk4ZXVVNldiVlh4WkFtNWo0QkQxcTNaVkZ4N0JKdzAtRDlKRWEzNlBQdW92N01ydmctb1RUalE?oc=5", "source_name": "Business Wire", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pfizer (PFE) Is Down 7.3% After Mixed Oncology Updates Reshape Its Long-Term Pipeline Narrative", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxQVERVWmhTd1AyZHB3SWFZbllxa0JqSWdLS3lUblo2WVJZYkgtTWJScUNlbXE2TFU1UGhDSVdIMTZxbnJXRGtxRDFvVEtZYkFJRmFvdXVEM2FQMl80RkMzUU92dFBQTDhUcEk5VXZMOENyWUZNTS1Pem1EQXNQUzJrRDc1NmxfYVE?oc=5", "source_name": "Market source", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pfizer (PFE) Falls More Steeply Than Broader Market: What Investors Need to Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPMEhoNTl1UEU0dVZJV01xQ0FaZks3OE5QZ1VubGNlYUNTOUZZM0M5dkxxeWFaRzdtSjMxYkh3dzc0LWtHOHdkYzJxVUk3YXBVbTRnSE56ZnRmRFVhRHktbF9QX3hTN2VWMHpwUkJOVllHakNhRTc0QWhEeV9BdXdnTzlXLWNHZVV6Y3F4SkRPakloVjJsZ24zUkp3?oc=5", "source_name": "Market source", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's When Pfizer's CEO Says the Company Might Get Back to Generating High-Single-Digit Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxOM3pTVVNFbHo0MjdlV3NPckRVM2RnczdHNnFFTXp1UDB5UkJRTlFYdGZUN2pfaUl5WDBlMEtoYlhyeWFkNWQteElJWkZEeEpLODhETUh1QWx5aGRXd0NURDV5aHFqbHdPRzl5ek5pWmw0NE1jbTBSZjBQYlJKTjJMdm03SDN2QXpVeVJxMk4tUmlzalFQc2o0dE51QQ?oc=5", "source_name": "Market source", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Sizzling 6.7% Dividend Yield? 1 Under-the-Radar Reason I Am Holding Off on Pfizer Stock at $25", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQSXJvRklCRkZvR2lkZGg0R2tXNzNkTGFRYVBHeEhVRWRSSnFmZDlPc20xUEhrVEU2OEFCYnVsVTJzMURvV2lJNnNOVU1QWEdocEdNUFBWTXJHcExUQUY2bzAzOHlHOXdrdDNBek14bGFFUTFJa2NVNExOSm5zV0xaeGJQNGhoUHN4X3QxTE5qeWhaeTV4ZWlETy03TXprRzY2Tm9POVlxU0VqUElDV0JGLWdPZUxiTzdkdmd5Z0w0bV9CTnIyLTlhMG94c3IweWI2NmJZ?oc=5", "source_name": "24/7 Wall St.", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here\u2019s Why Pfizer (PFE) Is One of the Most Undervalued US Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxONGR2YTIyUVRfMXFVTE5RdktrWkhIZENvaGlvQUtPR1d0bWhhYmlnVjN2MDUtSVdtZkwyTjJGWTVMY0NwTUFyZjRTWi0wMV9QenlfamUwUmFIY21tc2E5NVEzZG1yeUFIQ2Jfb0FXZEtJcDN2YThUSFBFUF96elZTbnhucHZnMGpDTl9qTWFPNTdUdjlaSkJn?oc=5", "source_name": "Market source", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pfizer Beats on Q1 Earnings, New & Acquired Drugs Drive Sales Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOS1p4Z3lKeVBSM0NucEkySjFJVmNNOGZLVjExZXA4N0dWTG4ycjFNbzlrS05TajJ6RWxrODJxZXJqVXdPeWE1ZGR5VVVzcEE4NmI0MkJheE9sbUdyUGNrNFZLMmdiZGdzU1BrLVRKNFducG1PTHJaOGdla2w5ZHg0YkVlaHFYM1RZOTE4NzJJSzF2Qy1sVkRpY2l0di1JbXRQMTB2R2VicDRVeVluSGs4eVRwVVlVT3NmdzFRZ1ZR?oc=5", "source_name": "TradingView", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Buy, Sell or Hold Pfizer Stock? Key Tips Ahead of Q1 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxOa2JoMWhFSF91Tkx2OWtCdm9Hd01JNi1iM1FibEJPX3NZWXRzLUlSMG9RZHJJMjM5aXR2RFpmZE9KN2h6TlFyMUNWZ3Q3V1BiNEM4ZWZCSXhvOTNsZ2o2al9XdTRmRXlqSTlIU3JFemJGMk1xck15blJsLVpOQ3dnOUZvSS14V2l5ejJxSm9sYjZKZ0ZtcVZvYlZGcXotNXhoXzNZSHp0a2QxME5uQ0Q4RHlZWW1fYldMTm1KSGxYUFd3bTdxSDBkT0dqdTFZbzBXMXBuNXVWQjUtd28?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pfizer's Non-Oncology Portfolio in Focus Ahead of Q1 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxPREFxWXRVM1IzSTVHN3NVcl9IMjZEd1R4SHcwR0gzOTZBMkhGejBDUUZfeXh2cnJzcHRkOS1BckliVXRjUkZPQTV2eG9kSFJtbGlROFR0XzVibjRfN1k3TGQ1M1hiNW5KMEFPUmZsLUl6aE9tTklvV2pjZkZpNVlWd2ZEQndFa19la2NzM0l5al81dkZodUt0Zk9QUE81U1RUaWozNUo3Sm9GNFBkR3UyTVZGdklmbk0xcVNQWDZQWXpVQXVRMEQ0TElLbGNDN1ZFWnRWN2RIbHBlVi1i?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Battle of Big Pharma: Is AbbVie Stock Pulling Ahead of Pfizer?", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOYlBqMWJXY0VmVmd5RndxcFFZeEFyRFFiRHNiQkdLN01yU2FoVWtPbFJkTVNhSGlQWXNxbXFFTE10eS12eGRRMXhzNkFCRnlFT0lFUzRVbVIzQXVCdWE1OEU2VFNXRHQyNFRVMmM5VTc0VGVZQjVnY0FUX0paZXA5NGZLWHJQTVlCVjc3MmVLY1h6MUlkUk55SHZ0UVFTQWVxcVlVcmlJbl9hRGdSczlVRHVkLUl5OFk?oc=5", "source_name": "TradingView", "published_at": "2026-04-10T07:00:00+00:00", "published_display": "10 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Pfizer (PFE)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE81NU1ReExNZE9vRmxfQmJUa2NpaEx1RTFQSm9IOGJHZVRRbVQ1ZzdtVDF2Z1EyV05Iam04VlhIN0d0a3BOQl9ab3lTdTlxYWg3eTZaYTdQSXVVM1BrVG5RbHJVbTBzSFRMVW5GVw?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-21T02:02:40+00:00", "published_display": "21 Mar 2026 02:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pfizer Stock: Buy, Sell or Hold After Its 11% Rally So Far in 2026?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPUFdqX3BuVDRrckFiY0ltdDBnQVFIY1FxdXZYcldJN2lyaGMxTEF4cWs3WHI0SXdoeHFieW9HN09RdXc4d3c5aURDbUhzQzVQMkJVTW1iWWhER1BzRm9STDQ2eEdjZ3VqdDhkZE1UOWVRam9kNmZmZW1nUUhFaDVLaDJ4QkN1MndTSXFLSDhyT1pPUldvVkFFNVdqd01KNW1OS2h4MXdVcFJuTEtlWk81Y3NJdmltYXVzM3Rz?oc=5", "source_name": "TradingView", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should You Buy, Sell or Hold Pfizer Stock After a Lukewarm Q4?", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxObEpyOWRCLTlJZnFYcGg2T3dlXzAxRDA0a1BndmZXdWpnLXNCVmJvZmc4NGpKcU9RQkkxN0VHR2U0SlNMUTlXU2Z6cWg5b3hrcTVxR3dmWEpWNW1meGRpdDVxbUZPZEVfbXlBcVJXM2VGdkR0WjdwUGUxVDcwR0JHazRjVjBYeU9DT2tpa3FQWFJwUGJrajRBa01fa1V1RExucGU4UWNQUHdzSm1kWUg2djYxcmtqMlE?oc=5", "source_name": "TradingView", "published_at": "2026-02-09T08:00:00+00:00", "published_display": "09 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "With 66% institutional ownership, Pfizer Inc. (NYSE:PFE) is a favorite amongst the big guns", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxQX1prdkRKVGJuWFB3WmVmMWlMTF9Ic1pldDZ4MUtoNkpEYXpsYmlKT0thZnBTVkxhS3phb2Jja0dTVi13UlA3SFBjTDBNT2FBOURZZzExbUhySmt1WXl1QlMxS2hXSWlCSzVTYnUyNVZFdVRJX2dXNS1FU0dSTTcxNTZQNHNVQUxqQ2xj?oc=5", "source_name": "Market source", "published_at": "2025-11-29T08:00:00+00:00", "published_display": "29 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "StockWatch: Pfizer\u2019s Deal with Trump Pays off for Investors", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNWXBTZGpfRnVnNjhQUTIzemxQUGFCaG9jWFVBc1R2bUZtTm1GTTRfWVlGMEZ0YVhqT2NCV2pfRDN1bXhFV1dfdzZ1bWd2ZFA4eV96RWFEOHhWZ2Ewa0YzUzdZQVJfYi0zRFNjSTJzX1NaanNRWUNQVm9XUkFMWVJHZER6dW1NSGN2eGRlV2VxaHVTN3lPdFZ4MTg1cVQ4VUFTclJ6bEZiTldPZw?oc=5", "source_name": "Genetic Engineering and Biotechnology News", "published_at": "2025-10-05T07:00:00+00:00", "published_display": "05 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "President announces TrumpRx and deal with Pfizer", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxOeWhrLUtPYWJUS0RIczZXd1N4Q1lSVFllLVlYUS02TzJab0psdWtZaTlxelVUcGdPTGJPcDZILWZaNnVUVm84Sm9MWGJJZkFmdGp2VksyZ1lVczRBMjNVbjA0Mm5KakstQTgta0NSYjNtS2ZhcVNkOElyM0dBZWhkVnpkSWhLNlg0MHJxZ1NaWQ?oc=5", "source_name": "Healthcare Finance News", "published_at": "2025-10-02T07:00:00+00:00", "published_display": "02 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Pfizer\u2019s Trump Deal Is Good News for All of Big Pharma", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxQSWVTeS1CUGdGUlpLRWd3N0Mtb1hPaVlIdFhRc0NLbjV3dnFfY3ItMXFhYTRGTlFZT0MxVHJRNW1jekZPbW1ubDg1YWZ5akwyaGZ6Zm9hLUtNWjUwc0hpRWU0N3h0aTUyZ1JGSGxzam1rMW0zTnpBYVE2YnZSVlZEUXNR?oc=5", "source_name": "WSJ", "published_at": "2025-10-02T07:00:00+00:00", "published_display": "02 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US Pfizer deal powers health stocks as drugmakers court Trump", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxNaUcxbjlfWGp2MzBmSGdvWThHdkJFMktJNHBPc2JxS0xrREV0M29ZRjFxeW9wRFBvOVVfT2FOUEQ1X2k5ZEIydElRdHJ6RGJ1Qi1vaEMtVlBqdjFQU1FvMkdwcXdoUUFHMXVhaE1lOFFTakpVMkZBdDFGbDhQbEpPenFTYVFfaWF6VllGeUF4ZVBTTU1ESXhmVmxiendLSnY0VnloZ3BSYTZveVB3b3EtbUFRZm9OVnNoaExTaWhoZ3NMdDdfX010b04zQ1ZhMDBqWS1pNnY1RzY3ZS02?oc=5", "source_name": "Reuters", "published_at": "2025-10-01T07:00:00+00:00", "published_display": "01 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trump, Pfizer agree to lower U.S. drug prices, exempt company from pharma tariffs", "summary": "", "url": "https://news.google.com/rss/articles/CBMiekFVX3lxTE8tZnBEa0xMWk5zTThqbW5hMTZFaGRxNTZUazNUMDRGWHFJSHVLZ3o1TkJBWUZRZlA4VmV0RkEteV8tb2FUbjItMWJCZnFNMnpKYnRINW96UlFtSGo2UVcxVjVLWW1OVklvbWRRNEFFTElJTTZuTlhxRlRB0gF_QVVfeXFMTzlSaDBMZ09sU1JIM1JlZXVCUzlOWEdaaGhNSjFYaWJNM3RvYXowRy10bFp3OUd1UHBTR1hqOS1ubWpTeGtpMEdYTE1HYTdvM3hlZDhNQTdScWVmWkhLai1MM1FwMkg5SFp0OUN2UTlaV3VSYWxITnJ2XzM0dUtVYw?oc=5", "source_name": "CNBC", "published_at": "2025-09-30T07:00:00+00:00", "published_display": "30 Sep 2025 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Is Earlier\u2011Stage PADCEV\u2011Keytruda Approval Reshaping The Investment Case For Pfizer (PFE)?", "summary": "Pfizer and Astellas recently secured FDA approval for PADCEV plus Keytruda for earlier-stage muscle-invasive bladder cancer, which broadens PADCEV\u2019s application and reinforces Pfizer's oncology focus. While this strengthens Pfizer\u2019s near-term cancer pipeline, the article notes th", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-pfe/pfizer/news/is-earlierstage-padcevkeytruda-approval-reshaping-the-invest", "source_name": "Simply Wall Street", "published_at": "2026-07-16T00:41:07", "published_display": "16 Jul 2026 00:41", "sentiment": "positive", "sentiment_pct": 62, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pfizer (NYSE:PFE) Faces New Patent Claim After $96 Billion in COVID Vaccine Revenue", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNWHpvSjBpa0ZYSi0tcWNuYWF1b2YxdVJNUzI2dmxKMUJxbTI2T2NCUHlIbHg3Q0doZ1VwTVZVa2hyUktfY1E2aE5IaC1NTlBrNjNCc3NwUHktdEVTekxkbHZGVTEyNHF1NzVURzJsT1A0b3V0QWxLQ1VpVnkwcHBoUTVwVXB5dlV5VjhnMGFGSmNkYTYtX0lIUkJBY2l2NTJnOEE?oc=5", "source_name": "TechStock\u00b2", "published_at": "2026-07-15T21:47:41+00:00", "published_display": "15 Jul 2026 21:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pfizer Inc. stock outperforms competitors on strong trading day", "summary": "Pfizer Inc. (PFE) saw its stock rise by 2.35% to $24.82 on Wednesday, outperforming the broader market as both the S&P 500 and Dow Jones Industrial Average also posted gains. The company's stock closed 13.65% below its 52-week high of $28.75, which was set on April 2nd. This perf", "url": "https://www.marketwatch.com/data-news/pfizer-inc-stock-outperforms-competitors-on-strong-trading-day-b26b3cad-228b8da1cb3c?mod=mw_quote_news", "source_name": "MarketWatch", "published_at": "2026-07-15T16:36:00", "published_display": "15 Jul 2026 16:36", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sanofi sues Pfizer, Moderna over COVID shot technology", "summary": "Sanofi has filed lawsuits against Pfizer and Moderna, alleging that their COVID-19 vaccines infringe on multiple patents held by the French pharmaceutical company. The lawsuits claim that the mRNA innovations used in Pfizer and Moderna's blockbuster vaccines violate Sanofi's pate", "url": "https://www.reuters.com/legal/litigation/sanofi-sues-pfizer-moderna-over-covid-shot-technology-2026-07-15/", "source_name": "Reuters", "published_at": "2026-07-15T16:04:03", "published_display": "15 Jul 2026 16:04", "sentiment": "negative", "sentiment_pct": 33, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sanofi Sues Moderna, Pfizer for Vaccine-Tech Patent Royalties", "summary": "Sanofi has filed federal lawsuits against Moderna and Pfizer, seeking patent royalties for their COVID-19 and RSV vaccines. Sanofi alleges that Moderna's Spikevax, mNexspike, and mResvia vaccines, and Pfizer's Comirnaty vaccine, infringe upon as many as 10 mRNA delivery patents h", "url": "https://news.bloomberglaw.com/ip-law/sanofi-sues-moderna-pfizer-for-vaccine-tech-patent-royalties", "source_name": "Bloomberg Law News", "published_at": "2026-07-15T14:59:10", "published_display": "15 Jul 2026 14:59", "sentiment": "negative", "sentiment_pct": 40, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pfizer (PFE) Announces FDA Approval of PADCEV plus Keytruda in MIBC", "summary": "Pfizer and Astellas Pharma announced FDA approval of PADCEV plus Keytruda as a neoadjuvant and adjuvant treatment for adult patients with muscle-invasive bladder cancer (MIBC), marking the first platinum-free regimen approved for MIBC regardless of cisplatin eligibility. This app", "url": "https://finance.yahoo.com/healthcare/articles/pfizer-pfe-announces-fda-approval-142445150.html", "source_name": "Market source", "published_at": "2026-07-15T14:24:46", "published_display": "15 Jul 2026 14:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is the Bearishness Around Pfizer and Gilead Sciences a Contrarian Opportunity?", "summary": "Pfizer and Gilead Sciences are presenting a contrarian investment opportunity as both stocks have experienced \"death crosses\" but trade below Wall Street consensus targets. Pfizer appears to be the more compelling contrarian setup due to its attractive 8x forward P/E and 7% divid", "url": "https://247wallst.com/investing/2026/07/15/is-the-bearishness-around-pfizer-and-gilead-sciences-a-contrarian-opportunity/", "source_name": "24/7 Wall St.", "published_at": "2026-07-15T13:10:37", "published_display": "15 Jul 2026 13:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celcuity gains FDA approval for closely-watched breast cancer drug", "summary": "Celcuity received FDA approval for its breast cancer drug Revtorpyk, to be used in combination with hormone therapy and Pfizer\u2019s Ibrance for certain advanced ER-positive, HER2-negative patients. Despite this regulatory win, Celcuity's shares fell due to unexpected launch timing a", "url": "https://finance.yahoo.com/healthcare/articles/celcuity-gains-fda-approval-closely-121800691.html", "source_name": "Market source", "published_at": "2026-07-15T07:18:00", "published_display": "15 Jul 2026 07:18", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pfizer (PFE) Wins FDA Approval For First Platinum Free Bladder Cancer Regimen", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/pfizer-pfe-wins-fda-approval-221544395.html", "source_name": "Simply Wall St.", "published_at": "2026-07-14T22:15:44+00:00", "published_display": "14 Jul 2026 22:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Structural Failure at Pfizer Conversion Project Triggers Citywide Construction Review", "summary": "A structural failure at the former Pfizer headquarters conversion project into 1,600 apartments in New York City has led to a citywide safety inspection of construction sites. Two steel columns buckled, causing floors to sag and prompting evacuations, raising concerns among inves", "url": "https://propmodo.com/structural-failure-at-pfizer-conversion-project-triggers-citywide-construction-review/", "source_name": "Propmodo", "published_at": "2026-07-14T22:09:05", "published_display": "14 Jul 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CELC Stock Clocks Best Day In About 2 Months On First FDA Approval For Cancer Drug", "summary": "Celcuity Inc. (CELC) shares surged 7% after the FDA approved its cancer drug, gedatolisib, in combination with fulvestrant, with or without Pfizer's palbociclib, for advanced hormone receptor-positive, HER2-negative breast cancer. This marks Celcuity's first marketed product, tra", "url": "https://finance.yahoo.com/healthcare/articles/celc-stock-clocks-best-day-212445145.html", "source_name": "Market source", "published_at": "2026-07-14T21:24:00", "published_display": "14 Jul 2026 21:24", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pfizer (PFE) Stock Looks Fully Priced After Its 21% Slump", "summary": "Pfizer (PFE) shares have declined by 21% over the past five years, placing its current valuation in a neutral position\u2014neither clearly cheap nor expensive. The stock trades at a P/E ratio of 18.7x, close to Simply Wall St's fair P/E of 19.6x, suggesting it is fairly valued within", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-pfe/pfizer/news/pfizer-pfe-stock-looks-fully-priced-after-its-21-slump", "source_name": "Simply Wall Street", "published_at": "2026-07-14T17:40:45", "published_display": "14 Jul 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pfizer Vs. Amgen: Bet That Pfizer's Seagen Integration Leads to Long-Term Oncology Alpha Over Amgen", "summary": "This article contrasts Pfizer and Amgen, arguing that Pfizer offers a better investment in oncology due to its successful integration of Seagen and existing revenue streams. Pfizer trades at a lower forward P/E of 8x with a substantial 7% dividend yield, while Amgen faces signifi", "url": "https://247wallst.com/investing/2026/07/14/pfizer-vs-amgen-bet-that-pfizers-seagen-integration-leads-to-long-term-oncology-alpha-over-amgen/", "source_name": "24/7 Wall St.", "published_at": "2026-07-14T15:51:00", "published_display": "14 Jul 2026 15:51", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pfizer Has the Highest-Yielding Dividend in the S&P 500. Should Investors Be Worried?", "summary": "Pfizer currently boasts the highest dividend yield in the S&P 500 at 7.1%, which is significantly above the average, leading some investors to worry about the safety of its dividend. While the high yield is partly due to a volatile share price, the company's recent earnings show ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/PFE/pressreleases/3276380/pfizer-has-the-highest-yielding-dividend-in-the-sp-500-should-investors-be-worried/", "source_name": "The Globe and Mail", "published_at": "2026-07-14T15:04:22", "published_display": "14 Jul 2026 15:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's What to Expect From Pfizer's Next Earnings Report", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNWXhwWVBRSW1NU094SEpZRU91S2RlTGVONmd2TUlCNVc2SUM5R1Q0am96ZFBmcDhPb0dXcE5fbExULTJNeFo4WHdQc0xEVGluNlVsN3dyaC1jM0ZaY1A3X3hfbEN5TTNuR2txWFdFNkpnUmlEdW1ER1JLOW13b09yUTVFUWtLOUJPcWhWS2Q0T3dDWXQ5dzRpdlljQm1uSGJP?oc=5", "source_name": "Market source", "published_at": "2026-07-14T14:02:32+00:00", "published_display": "14 Jul 2026 14:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's How Pfizer's Oncology Growth Story Looks Ahead of Q2 Results", "summary": "Pfizer is a leading oncology drugmaker, with oncology sales comprising about 27% of its total revenues. The company will announce its Q2 2026 results on August 4, with expectations of growth driven by drugs like Padcev, Lorbrena, and the Braftovi-Mektovi combination, alongside co", "url": "https://www.tradingview.com/news/zacks:349f5d7d4094b:0-here-s-how-pfizer-s-oncology-growth-story-looks-ahead-of-q2-results/", "source_name": "TradingView", "published_at": "2026-07-14T14:08:41", "published_display": "14 Jul 2026 14:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PFE stock holds steady as Pfizer focuses on core pharma portfolio", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxOWGJZXzNlNG9OSm1DaERNLXlCaDlJQXB4OTd0WkU2TGdFQy13a3c5UlZadWw1eVFqWEJFNVIwSlA4amJJUHdoZms5ZFVKbVBjTUlwZ3ZqdmJ5QU40RzJHMkdhV1RZdnVaTm95SmpOQ24tODN6ZHNSdjN6TFZTU1A5UE9NMzk2ZTJ2ajFZeU50ekRBVGNFYlBRWGJLcXFLVTYzYVRmdS15QUhFckFkSGdYT2pRamFFX1NQaE1qVUlkLU5iUQ?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-07-11T19:44:50+00:00", "published_display": "11 Jul 2026 19:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pfizer Stock Leads 3 AI Healthcare Picks Worth A Closer Look", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNNzlOaTl1Y1BydzVlbTk1eTR1S3J2RzltMXZ2dG9LcTlhTTY4LUJyMFJuOWFXOVpEZGVjTkRfYVRZY2k3RkR2eXFKTFFrc00tNE4taC1uSFRHM2NIajBaNTdJa2lEcVdwXzVSblF6d21kM1pmd3Izb3dtcGxEUDkyR204RXRZNl9HM1NfeWF1Y1BzT012YjhRRzBURE9qd1d4aXlyNHFHOXRKX1dueXQ5R0ZR?oc=5", "source_name": "Sahm", "published_at": "2026-07-10T07:00:00+00:00", "published_display": "10 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pfizer (PFE) Stock Sinks As Market Gains: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxNd1Q0MzYyc0JtUmFoanl5dGpTem9jcEdKX3lNLVRyb2x2Zk9nYW1BeW9RLWRJMGYzSmQ1Rm9QZHZ1MWZ1UkpwSXdCSk52dms0UF9SV2UxeC1VelVUaFdockhrWjhQejFHQzBxdWlBanp0UkFIeXBrczZGMVNHNkhsdHIzNHp3RkVJelI4VG5LWTNnUml6SEMwUy1n?oc=5", "source_name": "Market source", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pfizer Stock And 2 AI Healthcare Picks Investors May Want To Watch", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPczZzYmZKVXJQVjRibkVSQTVNVm4wWWZVVkxTdWhWdHpGQjlHdnhiZFNFeVo1clVGX3dGZDROaHdpQVVhMzd4X004MFFLRjJqcHVSYi0zUmlOYnI1bnppVWZocjNQUzQtcm1YVWpqSVVObXNXQjlaaGp1UFNYQm1MUUlFNDlPNGtweFVOcWE0WlBnSUg2bVhzY3UxNUhPT3BSeTE4MjdwN25xcHhSd0dyYnY1Y1Y0UlZmYkE?oc=5", "source_name": "Sahm", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pfizer (PFE) Stock May Be Fairly Priced On Its 22% Slide", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pfizer's CEO Says His Company Has a \"Very Big Balance Sheet\" to Do Deals. Here's the Perfect Next Acquisition Target for the Pharma Giant.", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxQQmFsaDgzZFl6bE5kNGVCcXo3aHQ2NWg3RUg2RnBCY1lqRWlvZFRCRDZsQUNxUURzdGtHNHBXUXgwaXN1VjhsMkVUNjdFbllTT2hMUDBlZXBsek1ieTJUTVJ5TUJtUW15Z2djV2dLYjhueHp6WGlCZHZFaXlsWURCSDdBZVdiT2hkQW5TdTZwMURrZDBY?oc=5", "source_name": "Market source", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pfizer vs Verizon Communications: Which High-Yielding Dividend Stock Is the Better Buy?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZVN0Mm1MbVVHeWxmOTJVUmtjQXVSd1JBNDlFdXdvaF9naDZ3SUFlelprRkxOTFdWYlc4R01maGh5Mzg3RVludGhGWEJCbXQwTldPSWpVeGZ6blV0NmVvUHIzNkx0S0p2ak11Z0JrYlpoaVpTb19aazdXQ19UNzVSV3dDbFZVU0pjWEUzRmhET2Z5YjRPM0FoZ3VmMXkzbEtJWDRFYQ?oc=5", "source_name": "Market source", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Pfizer (PFE) Stock Undervalued Despite Mixed Oncology Progress?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPRkFfTW1SRnRIbGhvUnVtZXZEYnBfVkYyNUljN053RUFOdHRFeXFZTmtwT0k3NlZLYkFyRXZ3MUVHaHJHSlJ0eWN5V3ZsOXlUS0xPamFHd2ZSZmZ4TDl1d1Y2M0RadFJtZ09iU01WdzU3bnZNV2J5WllmRFhMYnZWa245dW5VX3pqdW8yemJMMFlpa2JWZkpJOVpxUFZoeXFwUm93?oc=5", "source_name": "Market source", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pfizer (PFE) Stock Declines While Market Improves: Some Information for Investors", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNY0tRMEFHVTZfMl9weDBXMGdVSEFuVWRrN3ZtTk1kV1ZvczlnQ0hwMk5tX19NU0pBS0VfZWhERlNJelJzWGNLQWdHR2xPVGh5OXJVVGdBa3AtSnZMQlIwQTM1QUV5OEY1cFU2RUxhLVJ0Y1VWbG1PcmFUZm1HS05MamszX1k0QjJFRU5nWG9VN2ZKb2dDXzBZSmJTeEs?oc=5", "source_name": "Market source", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Pfizer Inc. (PFE) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOMk1TZ0EySmVsUmY0WXREekdZS2VQd1Q2dmpIRl8yX1dkdW8wMUIxTTFzN1FuTU9HUFZBQWJHOEd6ekU4QnNaZDZGVC1rRDVsaFdTUTVRZXBrLWxKSUM3Qi1xUXlwMGl0OWJ5NG01NWw3TkdraF80bVJuck1FTmNTbUxIWE84MWRVTkVieDBkbzlndEto?oc=5", "source_name": "Market source", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Opinion: Pfizer Is a Fantastic Dividend Stock for Income Investors to Buy Right Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOUkJhdGdKXzNZRVFXRWVHUTU1MHdzbW1GWno4dEV1VjdUQ3lJZFFQN2RoVXNGcUtadkZmUFNMcHFUQ0d0cUZDNVFFS04zbGNMUzB6SmpzV281ME93UjJNNURUSnJPR1lZaThDMGZZT3ZQeGRsQ2pZRDlRN094Y2drcjdQUFdIN1B1cVJrbGl2WExWRHJpRURWcVZoMTBHS2J1Y2c?oc=5", "source_name": "Market source", "published_at": "2026-06-27T07:00:00+00:00", "published_display": "27 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pfizer Declares Third-Quarter 2026 Dividend", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNRHNqVjBjcGJQd0g0SGhFNkdlVll5dmVqc1JVdjFTajJrX0lDWVVoNXprbWZtR09mdDItUDduRHNXVjd4TnhIRDJ4bGlmczdxdkFtd1JYT08yVy1wY2JqeEVhQ3JpTjBOR0YtSFk4ZXVVNldiVlh4WkFtNWo0QkQxcTNaVkZ4N0JKdzAtRDlKRWEzNlBQdW92N01ydmctb1RUalE?oc=5", "source_name": "Business Wire", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pfizer (PFE) Is Down 7.3% After Mixed Oncology Updates Reshape Its Long-Term Pipeline Narrative", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxQVERVWmhTd1AyZHB3SWFZbllxa0JqSWdLS3lUblo2WVJZYkgtTWJScUNlbXE2TFU1UGhDSVdIMTZxbnJXRGtxRDFvVEtZYkFJRmFvdXVEM2FQMl80RkMzUU92dFBQTDhUcEk5VXZMOENyWUZNTS1Pem1EQXNQUzJrRDc1NmxfYVE?oc=5", "source_name": "Market source", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pfizer (PFE) Falls More Steeply Than Broader Market: What Investors Need to Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPMEhoNTl1UEU0dVZJV01xQ0FaZks3OE5QZ1VubGNlYUNTOUZZM0M5dkxxeWFaRzdtSjMxYkh3dzc0LWtHOHdkYzJxVUk3YXBVbTRnSE56ZnRmRFVhRHktbF9QX3hTN2VWMHpwUkJOVllHakNhRTc0QWhEeV9BdXdnTzlXLWNHZVV6Y3F4SkRPakloVjJsZ24zUkp3?oc=5", "source_name": "Market source", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's When Pfizer's CEO Says the Company Might Get Back to Generating High-Single-Digit Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxOM3pTVVNFbHo0MjdlV3NPckRVM2RnczdHNnFFTXp1UDB5UkJRTlFYdGZUN2pfaUl5WDBlMEtoYlhyeWFkNWQteElJWkZEeEpLODhETUh1QWx5aGRXd0NURDV5aHFqbHdPRzl5ek5pWmw0NE1jbTBSZjBQYlJKTjJMdm03SDN2QXpVeVJxMk4tUmlzalFQc2o0dE51QQ?oc=5", "source_name": "Market source", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Sizzling 6.7% Dividend Yield? 1 Under-the-Radar Reason I Am Holding Off on Pfizer Stock at $25", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQSXJvRklCRkZvR2lkZGg0R2tXNzNkTGFRYVBHeEhVRWRSSnFmZDlPc20xUEhrVEU2OEFCYnVsVTJzMURvV2lJNnNOVU1QWEdocEdNUFBWTXJHcExUQUY2bzAzOHlHOXdrdDNBek14bGFFUTFJa2NVNExOSm5zV0xaeGJQNGhoUHN4X3QxTE5qeWhaeTV4ZWlETy03TXprRzY2Tm9POVlxU0VqUElDV0JGLWdPZUxiTzdkdmd5Z0w0bV9CTnIyLTlhMG94c3IweWI2NmJZ?oc=5", "source_name": "24/7 Wall St.", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here\u2019s Why Pfizer (PFE) Is One of the Most Undervalued US Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxONGR2YTIyUVRfMXFVTE5RdktrWkhIZENvaGlvQUtPR1d0bWhhYmlnVjN2MDUtSVdtZkwyTjJGWTVMY0NwTUFyZjRTWi0wMV9QenlfamUwUmFIY21tc2E5NVEzZG1yeUFIQ2Jfb0FXZEtJcDN2YThUSFBFUF96elZTbnhucHZnMGpDTl9qTWFPNTdUdjlaSkJn?oc=5", "source_name": "Market source", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pfizer Beats on Q1 Earnings, New & Acquired Drugs Drive Sales Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOS1p4Z3lKeVBSM0NucEkySjFJVmNNOGZLVjExZXA4N0dWTG4ycjFNbzlrS05TajJ6RWxrODJxZXJqVXdPeWE1ZGR5VVVzcEE4NmI0MkJheE9sbUdyUGNrNFZLMmdiZGdzU1BrLVRKNFducG1PTHJaOGdla2w5ZHg0YkVlaHFYM1RZOTE4NzJJSzF2Qy1sVkRpY2l0di1JbXRQMTB2R2VicDRVeVluSGs4eVRwVVlVT3NmdzFRZ1ZR?oc=5", "source_name": "TradingView", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Buy, Sell or Hold Pfizer Stock? Key Tips Ahead of Q1 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxOa2JoMWhFSF91Tkx2OWtCdm9Hd01JNi1iM1FibEJPX3NZWXRzLUlSMG9RZHJJMjM5aXR2RFpmZE9KN2h6TlFyMUNWZ3Q3V1BiNEM4ZWZCSXhvOTNsZ2o2al9XdTRmRXlqSTlIU3JFemJGMk1xck15blJsLVpOQ3dnOUZvSS14V2l5ejJxSm9sYjZKZ0ZtcVZvYlZGcXotNXhoXzNZSHp0a2QxME5uQ0Q4RHlZWW1fYldMTm1KSGxYUFd3bTdxSDBkT0dqdTFZbzBXMXBuNXVWQjUtd28?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pfizer's Non-Oncology Portfolio in Focus Ahead of Q1 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxPREFxWXRVM1IzSTVHN3NVcl9IMjZEd1R4SHcwR0gzOTZBMkhGejBDUUZfeXh2cnJzcHRkOS1BckliVXRjUkZPQTV2eG9kSFJtbGlROFR0XzVibjRfN1k3TGQ1M1hiNW5KMEFPUmZsLUl6aE9tTklvV2pjZkZpNVlWd2ZEQndFa19la2NzM0l5al81dkZodUt0Zk9QUE81U1RUaWozNUo3Sm9GNFBkR3UyTVZGdklmbk0xcVNQWDZQWXpVQXVRMEQ0TElLbGNDN1ZFWnRWN2RIbHBlVi1i?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Battle of Big Pharma: Is AbbVie Stock Pulling Ahead of Pfizer?", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOYlBqMWJXY0VmVmd5RndxcFFZeEFyRFFiRHNiQkdLN01yU2FoVWtPbFJkTVNhSGlQWXNxbXFFTE10eS12eGRRMXhzNkFCRnlFT0lFUzRVbVIzQXVCdWE1OEU2VFNXRHQyNFRVMmM5VTc0VGVZQjVnY0FUX0paZXA5NGZLWHJQTVlCVjc3MmVLY1h6MUlkUk55SHZ0UVFTQWVxcVlVcmlJbl9hRGdSczlVRHVkLUl5OFk?oc=5", "source_name": "TradingView", "published_at": "2026-04-10T07:00:00+00:00", "published_display": "10 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Pfizer (PFE)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE81NU1ReExNZE9vRmxfQmJUa2NpaEx1RTFQSm9IOGJHZVRRbVQ1ZzdtVDF2Z1EyV05Iam04VlhIN0d0a3BOQl9ab3lTdTlxYWg3eTZaYTdQSXVVM1BrVG5RbHJVbTBzSFRMVW5GVw?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-21T02:02:40+00:00", "published_display": "21 Mar 2026 02:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pfizer Stock: Buy, Sell or Hold After Its 11% Rally So Far in 2026?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPUFdqX3BuVDRrckFiY0ltdDBnQVFIY1FxdXZYcldJN2lyaGMxTEF4cWs3WHI0SXdoeHFieW9HN09RdXc4d3c5aURDbUhzQzVQMkJVTW1iWWhER1BzRm9STDQ2eEdjZ3VqdDhkZE1UOWVRam9kNmZmZW1nUUhFaDVLaDJ4QkN1MndTSXFLSDhyT1pPUldvVkFFNVdqd01KNW1OS2h4MXdVcFJuTEtlWk81Y3NJdmltYXVzM3Rz?oc=5", "source_name": "TradingView", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should You Buy, Sell or Hold Pfizer Stock After a Lukewarm Q4?", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxObEpyOWRCLTlJZnFYcGg2T3dlXzAxRDA0a1BndmZXdWpnLXNCVmJvZmc4NGpKcU9RQkkxN0VHR2U0SlNMUTlXU2Z6cWg5b3hrcTVxR3dmWEpWNW1meGRpdDVxbUZPZEVfbXlBcVJXM2VGdkR0WjdwUGUxVDcwR0JHazRjVjBYeU9DT2tpa3FQWFJwUGJrajRBa01fa1V1RExucGU4UWNQUHdzSm1kWUg2djYxcmtqMlE?oc=5", "source_name": "TradingView", "published_at": "2026-02-09T08:00:00+00:00", "published_display": "09 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "With 66% institutional ownership, Pfizer Inc. (NYSE:PFE) is a favorite amongst the big guns", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxQX1prdkRKVGJuWFB3WmVmMWlMTF9Ic1pldDZ4MUtoNkpEYXpsYmlKT0thZnBTVkxhS3phb2Jja0dTVi13UlA3SFBjTDBNT2FBOURZZzExbUhySmt1WXl1QlMxS2hXSWlCSzVTYnUyNVZFdVRJX2dXNS1FU0dSTTcxNTZQNHNVQUxqQ2xj?oc=5", "source_name": "Market source", "published_at": "2025-11-29T08:00:00+00:00", "published_display": "29 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "StockWatch: Pfizer\u2019s Deal with Trump Pays off for Investors", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNWXBTZGpfRnVnNjhQUTIzemxQUGFCaG9jWFVBc1R2bUZtTm1GTTRfWVlGMEZ0YVhqT2NCV2pfRDN1bXhFV1dfdzZ1bWd2ZFA4eV96RWFEOHhWZ2Ewa0YzUzdZQVJfYi0zRFNjSTJzX1NaanNRWUNQVm9XUkFMWVJHZER6dW1NSGN2eGRlV2VxaHVTN3lPdFZ4MTg1cVQ4VUFTclJ6bEZiTldPZw?oc=5", "source_name": "Genetic Engineering and Biotechnology News", "published_at": "2025-10-05T07:00:00+00:00", "published_display": "05 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "President announces TrumpRx and deal with Pfizer", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxOeWhrLUtPYWJUS0RIczZXd1N4Q1lSVFllLVlYUS02TzJab0psdWtZaTlxelVUcGdPTGJPcDZILWZaNnVUVm84Sm9MWGJJZkFmdGp2VksyZ1lVczRBMjNVbjA0Mm5KakstQTgta0NSYjNtS2ZhcVNkOElyM0dBZWhkVnpkSWhLNlg0MHJxZ1NaWQ?oc=5", "source_name": "Healthcare Finance News", "published_at": "2025-10-02T07:00:00+00:00", "published_display": "02 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Pfizer\u2019s Trump Deal Is Good News for All of Big Pharma", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxQSWVTeS1CUGdGUlpLRWd3N0Mtb1hPaVlIdFhRc0NLbjV3dnFfY3ItMXFhYTRGTlFZT0MxVHJRNW1jekZPbW1ubDg1YWZ5akwyaGZ6Zm9hLUtNWjUwc0hpRWU0N3h0aTUyZ1JGSGxzam1rMW0zTnpBYVE2YnZSVlZEUXNR?oc=5", "source_name": "WSJ", "published_at": "2025-10-02T07:00:00+00:00", "published_display": "02 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US Pfizer deal powers health stocks as drugmakers court Trump", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxNaUcxbjlfWGp2MzBmSGdvWThHdkJFMktJNHBPc2JxS0xrREV0M29ZRjFxeW9wRFBvOVVfT2FOUEQ1X2k5ZEIydElRdHJ6RGJ1Qi1vaEMtVlBqdjFQU1FvMkdwcXdoUUFHMXVhaE1lOFFTakpVMkZBdDFGbDhQbEpPenFTYVFfaWF6VllGeUF4ZVBTTU1ESXhmVmxiendLSnY0VnloZ3BSYTZveVB3b3EtbUFRZm9OVnNoaExTaWhoZ3NMdDdfX010b04zQ1ZhMDBqWS1pNnY1RzY3ZS02?oc=5", "source_name": "Reuters", "published_at": "2025-10-01T07:00:00+00:00", "published_display": "01 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trump, Pfizer agree to lower U.S. drug prices, exempt company from pharma tariffs", "summary": "", "url": "https://news.google.com/rss/articles/CBMiekFVX3lxTE8tZnBEa0xMWk5zTThqbW5hMTZFaGRxNTZUazNUMDRGWHFJSHVLZ3o1TkJBWUZRZlA4VmV0RkEteV8tb2FUbjItMWJCZnFNMnpKYnRINW96UlFtSGo2UVcxVjVLWW1OVklvbWRRNEFFTElJTTZuTlhxRlRB0gF_QVVfeXFMTzlSaDBMZ09sU1JIM1JlZXVCUzlOWEdaaGhNSjFYaWJNM3RvYXowRy10bFp3OUd1UHBTR1hqOS1ubWpTeGtpMEdYTE1HYTdvM3hlZDhNQTdScWVmWkhLai1MM1FwMkg5SFp0OUN2UTlaV3VSYWxITnJ2XzM0dUtVYw?oc=5", "source_name": "CNBC", "published_at": "2025-09-30T07:00:00+00:00", "published_display": "30 Sep 2025 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 108, "total_relevant": 46, "sentiment_summary": {"positive": 12, "negative": 5, "neutral": 29, "score": 53, "total": 46, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 76, "events": [{"event": "general", "label": "Market update", "weight": 12.8, "count": 22}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 4.55, "count": 7}, {"event": "earnings", "label": "Earnings", "weight": 4.4, "count": 8}, {"event": "deals", "label": "Deals and strategy", "weight": 3.45, "count": 5}, {"event": "capital_return", "label": "Capital return", "weight": 2.2, "count": 4}], "positive_events": 12, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 24.17, "latest_week": "2026-07-10", "one_week_move": -0.6, "four_week_move": -7.8, "twelve_week_move": -10.8, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.993759, "market_dynamics_buy_signal": false, "relative_strength": -12.815388, "fair_value_gap": -2.3, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 52.0193, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-0.6% over one week, -7.8% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 50, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 16}, {"label": "TradingView", "count": 5}, {"label": "24/7 Wall St.", "count": 3}, {"label": "The Globe and Mail", "count": 3}, {"label": "Simply Wall Street", "count": 2}, {"label": "Reuters", "count": 2}, {"label": "Sahm", "count": 2}, {"label": "TechStock\u00b2", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 46}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 22}, {"label": "Earnings", "count": 8}, {"label": "Regulatory and legal", "count": 7}, {"label": "Deals and strategy", "count": 5}, {"label": "Capital return", "count": 4}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "46", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "6", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-0.6% over one week, -7.8% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Is Earlier\u2011Stage PADCEV\u2011Keytruda Approval Reshaping The Investment Case For Pfizer (PFE)?"}], "updated_at": "2026-07-16T07:07:36.536405+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}